NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Vivatides Therapeutics

Vivatides Therapeutics

Private
Woburn, MassachusettsHealthcare & Life Scienceshttps://biopharmaapac.com/

Last Round

Series A

Apr 10, 2026

Total Funding Raised

$64M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Vivatides Therapeutics is a biotechnology company developing extrahepatic RNA-targeting therapeutics, including small interfering RNA (siRNA) and antisense oligonucleotides (ASOs), to treat chronic conditions.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

custom peptide synthesispeptide synthesishigh-purity peptidescatalog peptideslife science reagentscontract research organizationCRObiomanufacturing servicespeptide modificationpeptide analysisdrug discovery servicesCDMOepitope mapping

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vivatides Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Vivatides Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Vivatides Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 10, 2026
SeedAug 22, 2025

Vivatides Therapeutics Investors

Notable investors and investment history

Vivatides Therapeutics investors
InvestorRounds
Highlight CapitalSeries A
TF CapitalSeries A
Qiming Venture PartnersSeed, Series A
Apricot CapitalSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 10, 2026

    Raised $54M in Series A funding.

  • Aug 22, 2025

    $10M raised in Seed round.

Vivatides Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Vivatides Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vivatides Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWoburn, Massachusetts
Year Founded2025
Last FundingApr 10, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.